golimumab golimumab golimumab is a human monoclonal antibody which is used as an immunosuppressive medication and sold under the brand name simponi. golimumab targets tumor necrosis factor alpha (tnf-alpha), a pro-inflammatory molecule and hence is a tnf inhibitor. profound reduction in c-reactive protein (crp) levels, interleukin (il)-6, intercellaular adhesion molecules (icam)-1, matrix metalloproteinase (mmp)-3, and vascular endothelial growth factor (vegf) demonstrates golimumab as an effective modulator of inflammatory markers and bone metabolism. golimumabcartoon representation of the antibody golimumab's variable fragment. the heavy and light chain fragments are coloured blue and yellow, respectively. from pdb entry 5yoymonoclonal antibodytypewhole antibodysourcehumantargettnfαclinical datatrade namessimponi, simponi ariaother namescnto-148ahfs/drugs.commonographmedlineplusa610010license data eu ema: by inn us dailymed: golimumab us fda: golimumab pregnancycategory au: c routes ofadministrationsubcutaneous injectionatc codel04ab06 (who) legal statuslegal status au: s4 (prescription only) uk: pom (prescription only) us: ℞-only eu: rx-only identifierscas number476181-74-5 ndrugbankdb06674 ychemspidernoneunii91x1klu43ekeggd04358 ychemblchembl1201833 necha infocard100.226.360 chemical and physical dataformulac6530h10068n1752o2026s44molar mass146945.25 g·mol−1 ny (what is this?) (verify) it is on the world health organization's list of essential medicines. golimumab was developed by janssen biotech, inc. (formerly centocor biotech, inc.) which also markets the product in the united states. the janssen pharmaceutical companies market simponi in canada, central and south america, the middle east, africa and asia pacific. in europe, russia and turkey, simponi distribution rights are held by schering-plough (ireland) company, a subsidiary of merck & co., inc. in japan, indonesia and taiwan, distribution rights are held by mitsubishi tanabe pharma corporation. development golimumab binds to both soluble and transmembrane forms of tnfα. the antibody was isolated from a hybridoma clone produced by transgenic mice immunized with human tnfα. the golimumab-secreting clone was selected after being assayed for human light and heavy chains and tnfα-binding. the commercial product is produced in a recombinant cell line cultured by continuous perfusion. uses : approvals and indications the european medicines agency (ema) has approved the use of golimumab as a treatment for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. golimumab was approved for the treatment by the us food and drug administration (fda) as well as the european medicines agency (ema) in 2013 for the treatment of ulcerative colitis. golimumab can either be used via a self administered subcutaneous injection or intravenous injection. golimumab is approved in canada and the united states as a once monthly subcutaneous treatment for adults with moderately to severely active rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis and ankylosing spondylitis. research rheumatoid arthritis large, double-blind randomized controlled trials in patients with rheumatoid arthritis have shown that golimumab in combination with methotrexate was more effective than methotrexate alone. when clinically indicated, golimumab is estimated as a moderate cost-effective treatment option. national institutes for health and care excellence (nice) stated that treatment with golimumab is recommended for ra patients who have failed prior tnfi treatment. unlike other tnfi treatments such as adalimumab and certolizumab pegol, there have been no reported cases of drug-induced lupus-like syndrome (dils). uveitis there is preliminary evidence for golimumab as a treatment option for ocular inflammation.